India reported less than 20,000 new COVID-19 cases (19,740) in the last 24 hours, seven per cent lower than yesterday’s figure when the country recorded 21,257 cases. The country also reported 248 deaths due to coronavirus.The active COVID-19 cases in India comprise 0.70 per cent of the total infections, the lowest since March 2020 — the active caseload at present is 2,36,643, lowest in 206 days.
The national COVID-19 recovery rate was recorded at 97.98 per cent, highest since March 2020. At least 23,070 recoveries in the last 24 hours took the total number of recoveries to 3,32,48,291 in India.
The daily positivity rate – number of positive cases identified per 100 – stands at 1.56 per cent, less than 3 per cent for last 40 days. The weekly positivity rate stands at 1.62 per cent in India.Over 93.99 crore vaccine doses have been administered so far under Nationwide Vaccination Drive in India.
Kerala reported 10,944 fresh COVID-19 cases and 120 deaths, taking the infection count to 47,74,666 and fatalities to 26,072. Amid protest by the opposition alleging under-reporting of COVID deaths in Kerala, the state government has decided to include 7,000 more victims of the pandemic in its official death list.
Delhi recorded zero death due to COVID-19 and 39 fresh cases with a positivity rate of 0.06 per cent. According to a Delhi Disaster Management Authority order, Delhi government employees and teachers who have not received at least one shot of COVID-19 vaccine will not be allowed to attend their workplaces from October 16.
Maharashtra reported 2,620 new coronavirus cases which took the state’s caseload to 65,73,092. Out of these, Mumbai reported 532 new COVID-19 cases and 8 deaths.
The COVID-19 tally in West Bengal increased to 15,74,801 after the state reported 784 fresh cases, the health department said in a bulletin.
Mizoram reported 950 new COVID-19 cases and one death in the last 24 hours, said the state health bulletin.
Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of Merck & Co’s oral antiviral drug molnupiravir for moderate COVID-19, raising questions about how effective the experimental medicine is for that group of patients.